Peter Radovich
2022
In 2022, Peter Radovich earned a total compensation of $1.6M as Chief Operating Officer at Mirum Pharmaceuticals, a 13% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $252,450 |
|---|---|
| Option Awards | $670,596 |
| Salary | $467,500 |
| Stock Awards | $158,700 |
| Other | $12,200 |
| Total | $1,561,446 |
Radovich received $670.6K in option awards, accounting for 43% of the total pay in 2022.
Radovich also received $252.5K in non-equity incentive plan, $467.5K in salary, $158.7K in stock awards and $12.2K in other compensation.
Rankings
In 2022, Peter Radovich's compensation ranked 2,156th out of 5,760 executives tracked by ExecPay. In other words, Radovich earned more than 62.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,156 out of 5,760 | 63rd |
Division Manufacturing | 1,160 out of 3,136 | 63rd |
Major group Chemicals And Allied Products | 500 out of 1,422 | 65th |
Industry group Drugs | 460 out of 1,323 | 65th |
Industry Pharmaceutical Preparations | 334 out of 969 | 66th |
Source: SEC filing on May 1, 2023.
Radovich's colleagues
We found three more compensation records of executives who worked with Peter Radovich at Mirum Pharmaceuticals in 2022.
News
Mirum Pharmaceuticals CEO Christopher Peetz's 2023 pay jumps 47% to $6.5M
April 23, 2024
Mirum Pharmaceuticals CEO Christopher Peetz's 2022 pay rises 7% to $4.4M
May 1, 2023
Mirum Pharmaceuticals CEO Christopher Peetz's 2021 pay jumps 38% to $4.1M
April 22, 2022
Mirum Pharmaceuticals CEO Christopher Peetz's 2020 pay falls 52% to $3M
April 14, 2021